Xlife Sciences AG (XSWX:XLS) Net Income: CHF-21.55 Mil (TTM As of Dec. 2025)


XSWX:XLS Xlife Sciences AG XSWX:XLS
53 GF Score
Price CHF18.00
GF Value CHF7.26
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Net Income?

Xlife Sciences AG XSWX:XLS +1.12% 53 Net Income is CHF-21.55 Mil as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.26 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Xlife Sciences AG's Net Income for the six months ended in Dec. 2025 was CHF-18.50 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-21.55 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Xlife Sciences AG's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was CHF-2.53.


Xlife Sciences AG  (XSWX:XLS) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Xlife Sciences AG's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Xlife Sciences AG Net Income Related Terms


Xlife Sciences AG Net Income Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Net Income Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income
Get a 7-Day Free Trial 53.42 14.31 14.88 34.28 -21.55

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.76 0.47 33.80 -3.05 -18.50
XSWX:XLS
53GF Score
Xlife Sciences AG XSWX:XLS
Net Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Xlife Sciences AG's Net Income for the fiscal year that ended in Dec. 2025 is calculated as

Net Income(A: Dec. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-31.86+4.739+0+5.574
=-21.55

Xlife Sciences AG's Net Income for the quarter that ended in Dec. 2025 is calculated as

Net Income(Q: Dec. 2025 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-23.656+2.37+0+2.789
=-18.50

Net Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-21.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Income →
What does a Net Income of CHF-21.55 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a Net Income of CHF-21.55 Mil as of Dec. 2025. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Net Income too high?
Xlife Sciences AG's current Net Income is CHF-21.55 Mil. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Net Income compare to VRTX and REGN?
Xlife Sciences AG's Net Income of CHF-21.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Biotechnology company?
A good Net Income depends on the Biotechnology industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Net Income is CHF-21.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.26, compared to a current price of CHF18.00 — trading 147.9% above its estimated fair value. The current Net Income is CHF-21.55 Mil. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Net Income is CHF-21.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF18.00 is trading 147.9% above its estimated GF Value™ of CHF7.26. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Net Income: CHF-21.55 Mil
  • GF Value™: CHF7.26 vs. price of CHF18.00 (147.9% above fair value)
  • GF Score™: 53/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score

Get the complete analysis for XSWX:XLS

Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.00
Price
CHF7.26
GF Value